Taxotere combination approved for induction therapy in SCCHN

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 10
Volume 16
Issue 10

FDA has approved Sanofi-Aventis' Taxotere (docetaxel) for use in combination with cisplatin and fluorouracil (TPF) for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)

ROCKVILLE, Maryland—FDA has approved Sanofi-Aventis' Taxotere (docetaxel) for use in combination with cisplatin and fluorouracil (TPF) for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).

FDA based its approval on TAX- 324, a multicenter, open-label, randomized trial of 501 patients. Overall survival was significantly prolonged with the Taxotere-containing regimen, compared with PF alone (P = .0058). Median survival was 70.6 months in the TPF group vs 30.1 months in the PF group (HR 0.70).

Recent Videos
Treatment with toripalimab does not yield the same vascular toxicity seen with pembrolizumab in patients with advanced or metastatic nasopharyngeal carcinoma, according to Barbara Burtness, MD.
Overall survival also appears to improve with toripalimab compared with chemotherapy among patients with metastatic or advanced nasopharyngeal carcinoma.
head and neck cancer
head and neck cancer
head and neck cancer
Related Content